Saturday, July 24, 2010
Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer (see 'Note')
Note: while not ovarian cancer specific (noting the common cell type of clear cell) the conclusion is interesting
CONCLUSION: We identified overweight as an independent prognostic marker of improved cancer specific survival in patients with organ-confined but not advanced RCC. Basic research is required to resolve the dilemma of why, if a higher BMI predisposes to RCC, it concurrently prolongs survival after patients have undergone (partial) nephrectomy.
Program SlidesInteractive Case #1—Primary ovarian cancer: What’s optimal surgery?
Interactive Case #2—Initial systemic therapy for ovarian cancer
Interactive Case #3—Recurrent ovarian cancer: Partially platinum–sensitive (Recurrence after 6-12 months)
Interactive Case #4—Stage IIIB ovarian cancer: Recurrence >12 months following completion of induction chemotherapy
—Progress report on novel & targeted therapies for ovarian cancer
Interactive Case #5—Platinum resistant/refractory ovarian cancer: Optimizing quality of life
".....In the first of a series of major breakthroughs in this past year, a pioneering team of ovarian cancer researchers, led by the Agency’s Dr. David Huntsman, found the single genetic mutation or “spelling mistake” in the three billion “letters” that make up the genetic code of an ovarian tumour cell.
This was a true eureka moment for Huntsman’s team. They recognized that this one consistent mutation could be the bull’s eye target in developing new treatments for all patients with this particular cancer. Their game-changing discovery was published in the prestigious New England Journal of Medicine and widely acknowledged in the global cancer community.
The next-generation computer technology provided by the BC Cancer Agency’s Genome Sciences Centre that decoded and sequenced the tumour cell’s three-billion-letter genome is another milestone achievement. A genomic task of this magnitude was unfathomable, in terms of both cost and complexity, even two years ago."
INTRODUCTION: Carcinoid tumors are uncommon neoplasms in the diffuse peripheral endocrine system. Ovarian carcinoids are rare and can be primary or transplanted. Primary ovarian carcinoids make up approximately 0.5-1.7% of all carcinoid tumors.
.....The immunohistochemical study revealed a neuroendocrine origin with strong positivity for NSE, CgA and Syn. Other markers, such as a-inhibin and Calretinin, were negative. Finally, the case was diagnosed as a primary ovarian trabecular carcinoid tumor.
CONCLUSION: Primary ovarian trabecular carcinoid tumors are very rare. The patients lack clinical indicators, and final diagnosis depends on pathological examination, special staining and inmmunohistochemistry staining to confirm the neuroendocrine differentiation.
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation
"We recommend that all suspected HBOC families from Portugal or with Portuguese ancestry are specifically tested for this rearrangement (BRCA2 c.156_157insAlu)."